金沙(8888js-官方JS认证)-Made in China

Be the most trusted biotech company

2023-05-26

Results from the Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-line Treatment of ESCC Released at 2023 ASCO Annual Meeting
2023-05-19

Henlius Will Be at BIO 2023
2023-05-17

Phase I Clinical Results of Henlius HLX22, an innovative anti-HER2 mAb, Published in Investigational New Drugs
2023-05-10

Frontiers in Immunology has Published Results from the Phase 2 Clinical Study of HANSIZHUANG Plus Chemotherapy for the Treatment of Advanced Cervical Cancer
2023-05-08

Henlius to Present Clinical Data at 2023 ASCO Annual Meeting Highlighting Promising Pipelines and Significant Progress
2023-05-06

Henlius Hosts Clinical Investigators Meeting for ASTRIDE Study in the U.S.
2023-05-05

IND application of phase 2 clinical trial of HANSIZHUANG in combination with novel anti-LAG-3 mAb and chemotherapy for the first-line treatment of advanced non-small cell lung cancer patients was approved by NMPA
2023-04-26

A Solid Foundation of Sustainability, Henlius Releases 2022 ESG Report
2023-04-16

Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged

1
...
3
4
5
6
7
8